RESEARCH
LATEST
FULL LIST
-
Revalia Bio Secures ~$30M Government Contract to Build the Future of Human-First Drug Development
Revalia Bio, a Yale-born startup redefining drug development through real human donor tissue, has secured a landmark ~$30 million U.S. government contract—one of the largest ever awarded to a seed-stage biotechnology company. The announcement marks a turning point not only for Revalia, but for the broader movement away from animal-model drug development and toward human-first…
-
JETT: Connecting Innovators with the Joint Chem Bio Enterprise
The Joint Enterprise Technology Tool (JETT) is reshaping how innovators engage with the U.S. government’s chemical and biological defense community. Designed as a direct bridge between the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) and industry, JETT makes collaboration faster, clearer, and more impactful. If you’re developing a technology that…
-
NIH Launches Nation’s First Dedicated Organoid Development Center
The National Institutes of Health (NIH) has announced the creation of the nation’s first dedicated organoid development center, marking a pivotal step in reducing reliance on animal models for biomedical research. The new Standardized Organoid Modeling (SOM) Center, located at the Frederick National Laboratory for Cancer Research, will receive $87 million over the next three…
-
MIT and Polimi Develop Low-Cost AI Monitoring System to Improve 3D Bioprinting of Engineered Tissues
A collaborative research team from the Massachusetts Institute of Technology (MIT) and the Polytechnic University of Milan (Polimi) has introduced a modular, printer-agnostic monitoring platform designed to enhance the quality and efficiency of 3D bioprinting for tissue engineering. This development addresses a longstanding challenge in the field: the lack of integrated process control, which often…
-
Instant Collagen, Real-Time Biofabrication: What TRACE Means for the Lab & the Market
Nature Materials has just published a paper that’s turning heads across the biofabrication community. Gong et al. describe TRACE – Tunable Rapid Assembly of Collagenous Elements, a macromolecular-crowding approach that lets unmodified type I collagen gel in seconds while staying pH-neutral and fully bioactive. The article racked up 9,899 views, an Altmetric score of 39,…
-
CollPlant Expands U.S. Footprint with Strategic Hire to Lead Commercial GrowthBusiness of Biofabrication
CollPlant Biotechnologies (NASDAQ: CLGN), a leader in recombinant human collagen (rhCollagen) innovation, has appointed Bowman Bagley as Vice President, Commercial North America. The newly created position underscores CollPlant’s growing commitment to scaling its regenerative medicine and bioprinting platforms across the U.S. and Canadian markets. Leadership with Deep Roots in Biomaterials Bagley, an experienced executive in…
-
Tides Medical and UToledo Health Pioneer 3D Bioprinted Grafts for Chronic Wound Care
UToledo Health has become one of the first healthcare systems in the U.S. to implement 3D bioprinted grafts derived from a patient’s own fat cells in the treatment of chronic wounds. The approach marks a major advancement in regenerative medicine, offering a personalized solution for patients with wounds that have resisted conventional healing methods. A…
-
Stanford Accelerates Vascular Modeling for Organ Bioprinting
New algorithm offers scalable design pathway for patient-specific blood vessel networks Addressing a Core Challenge in Biofabricated Organs Stanford researchers have introduced a computational tool that could remove a major roadblock in organ bioprinting: the creation of functional, patient-specific vascular networks. Their new platform, published in Science on June 12, 2025, enables the rapid design…
-
Vital3D Targets Pet Care Market as Strategic Entry Point to Bioprinted Human Organs
Commercial Focus Begins with Veterinary Wound Care Lithuanian startup Vital3D is positioning itself at the forefront of bioprinted organ development, with a projected timeline of 10 to 15 years for human applications. As a first step toward that goal, the company is entering the market with VitalHeal, a 3D-bioprinted wound patch for pets — beginning…
-
Collagen-Based 3D Bioprinting Offers Fully Perfusable Gel Based Organ-On-Chips
A team of bioengineers at Carnegie Mellon University has unveiled a new tissue engineering platform. The study, published in Science Advances, introduces CHIPS (Collagen-based High-resolution Internally Perfusable Scaffolds), a new class of biological, perfusable 3D-printed tissue constructs, and VAPOR, a customizable perfusion bioreactor designed to support them. What’s the Technology? The platform uses an improved…
Subscribe
Enter your email below to receive updates.
The Business of Biofabrication 